Diphenhydramine Hydrochloride Injection, USP

Diphenhydramine hydrochloride, USP is an antihistamine drug having the chemical name 2- (Diphenylmethoxy)-N, N-dimethylethylamine hydrochloride. It occurs as a white, odourless, crystalline powder, is freely soluble in water and alcohol and has a molecular weight of 291.8. The molecular formula is C ₁₇H ₂₁NO • HCl. The structural formula is as follows:

Diphenhydramine hydrochloride, USP in the parenteral form is a sterile, pyrogen-free solution available in a concentration of 50 mg of diphenhydramine hydrochloride, USP per mL. The solutions for parenteral use have been adjusted to a pH between 5.0 and 6.0 with either sodium hydroxide or hydrochloric acid and contains 0.1 mg/mL benzethonium chloride as a germicidal agent.

Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.

Diphenhydramine hydrochloride injection, is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical.

Antihistaminic

For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.

Motion sickness

For active treatment of motion sickness.

Antiparkinsonism

For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combinations with centrally acting anticholinergic agents.

Use in Neonates or Premature Infants

This drug should notbe used in neonates or premature infants.

Use in Nursing Mothers

Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Use as a Local Anesthetic

Because of the risk of local necrosis, this drug should not be used as a local anesthetic.

Antihistamines are also contraindicated in the following conditions:

Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.

Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine hydrochloride.

Use in Pediatric Patients

In pediatric patients, especially, antihistamines in overdosagemay cause hallucinations, convulsions, or death.

As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.

Use in the Elderly (approximately 60 years or older)

Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

The most frequent adverse reactions are underscored.

1. General:Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose, and throat
2. Cardiovascular System:Hypotension, headache, palpitations, tachycardia, extrasystoles
3. Hematologic System:Hemolytic anemia, thrombocytopenia, agranulocytosis
4. Nervous System:Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions
5. GI System:Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation
6. GU System:Urinary frequency, difficult urination, urinary retention, early menses
7. Respiratory System:Thickening of bronchial secretions, tightness of chest or throat and wheezing, nasal stuffiness

To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA Inc., at 1-855-839-8195 or FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch.

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms; dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

Stimulantsshould not be used.

Vasopressors may be used to treat hypotension.

THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.

Diphenhydramine hydrochloride injection, is indicated when the oral form is impractical.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

Pediatric Patients, other than premature infants and neonates

5 mg/kg/24 hr or 150 mg/m ²/24 hr. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.

Adults

10 mg to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly, 100 mg if required; maximum daily dosage is 400 mg.

Diphenhydramine hydrochloride injection, USP is supplied as a clear, colorless sterile solution containing 50 mg diphenhydramine hydrochloride in each milliliter of solution with 0.1 mg/mL benzethonium chloride as a germicidal agent.

10 mL fill in 10 mL vial:                                NDC 42571-511-56

Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature].

Protect from freezing and light.

Manufactured by:

Micro Labs Limited

Bangalore-560099, INDIA

Manufactured for:

Micro Labs USA, Inc.

Somerset, NJ 08873

Rev. 07/2024

NDC 42571-511-56 
diphenhydrAMINE Hydrochloride Injection, USP
500 mg/10 mL (50 mg/mL)
For Intravenous or Intramuscular Use
HIGH POTENCY
10 mL Multi-Dose Vial
Rx only

diphenhydramine-lbl.jpg

diphenhydramine-crt.jpg